Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $102.300M Est
Gyre Therapeutics (NASDAQ: GYRE ) affirms FY2026 sales outlook from $100.500 million-$111.000 million to $100.500 million-$111.000 million vs $102.300 million estimate.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.